RoivantROIV
NASDAQPharmaceuticals
No cached AI snapshot yet for ROIV.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
750 employees715.70M shares outstandinglisted 2021-10-01
Next earnings ~May 5, 2026
About Roivant
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Latest News
Showing market-wide stock news
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story
Treasury ETF shorts shift toward belly ahead of Fed decision
BoE to 'stand ready to hike', committee remains 'deeply divided'
The Fed’s interest rate decision in the epicenter of attention
News Flash: 70% of Wall Street Institutions Are Calling for at Least a 50-Basis-Point Fed Rate Hike in 2026
Related Stocksin Pharmaceuticals
Ready to see the live AI view on ROIV?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing ROIV side-by-side with live signals.